Business
MedMira Expands Multiplo Product Range with Three New Rapid Vertical Flow Tests
New Tests Delivering Instant, Simultaneous Results for Syphilis, HIV, and Hepatitis C in ...
About this update from Medmira Inc.
[{"type":"text","content":"\n\n\nNew Tests Delivering Instant, Simultaneous Results for Syphilis, HIV,\n and Hepatitis C in Three Distinct Combinations to Debut at 2014 AACC\n Annual Meeting\n\n\nHALIFAX, July 16, 2014 /CNW/ - MedMira, Inc. (MedMira) (TSXV: MIR) is\n expanding its Multiplo product line with the addition of three new multiplex tests that\n deliver instant, simultaneous, single-cartridge results for syphilis\n (TP), HIV, and hepatitis C.  The new tests being added to the product\n range include Multiplo TP/nTP, which detects both active and historic\n syphilis infections, Multiplo TP/HIV/nTP, and Multiplo TP/HIV/HCV,\n which simultaneously detects syphilis, HIV and hepatitis C.\n\n\nThe full Multiplo line is now available in international markets with\n analysis of highly regulated markets, possibly including North America\n and Europe, underway. MedMira will showcase its full Multiplo line for\n the first time at the 2014 American Association for Clinical Chemistry\n (AACC) Annual Meeting & Clinical Lab Expo.\n\n\nThe new tests all deliver instant results for syphilis infection, a\n disease with an increasing global prevalence rate. Multiplo TP/nTP and\n Multiplo TP/HIV/nTP take testing a step further, providing\n comprehensive screening and confirmatory results for both present and\n past syphilis infections.  Detecting the presence of both current and\n previous infections provides critical information to help healthcare\n providers in determining the right course of treatment for their\n patients.\n\n\n\"The creativity and innovation powered by our patented RVF Technology is\n limitless and this expansion of our Multiplo product range is a prime\n example of how the technology enables new rapid tests to fast track\n through discovery, design, and development to meet customer demands,\"\n said Dr. Kevin Jones, Senior Director Sales & Marketing, MedMira.  \"The\n WHO has identified syphilis as a serious global healthcare issue and\n our Multiplo tests will prove invaluable in large scale testing\n programs targeting multiple diseases, especially prenatal maternal\n initiatives.  Multiplo TP/HIV is currently under evaluation as part of\n the WHO prequalification program and we look forward to working with\n them to bring our newest Multiplo tests to screening programs around\n the world.\"\n\n\nThe World Health ...